Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin

Journal of Diabetes and its Complications

Volumn 17, Issue 6, 2003, Pages 307-313

  Kilo, Charles ^a   Mezitis, Nicholas ^b   Jain, Rajeev ^c   Mersey, James ^d   McGill, Janet ^e   Raskin, Philip ^f  

^a Kilo Clinical Research Limited   (United States)

^b Mezitis Educ and Research Institute   (United States)

^c Advanced Healthcare   (United States)

^d Universal Clinical Research Center Inc   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Biphasic insulin; Biphasic insulin aspart; Insulin; Insulin aspart; Insulin initiation; Metformin; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; HUMAN INSULIN; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 0142138134     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(03)00076-X     Document Type: Article

References (20)

1. Alberti K.G.M.M., Gries F.A., Jervell J., Krans H.M.J. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Medicine. 11:1994;889-909.
2. American Diabetes Association Screening for type 2 diabetes. Diabetes Care. 23(S1):2000;S20-S23.
3. Aviles-Santa L., Sinding J., Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 131:1999;182-188.
4. Bastyr E.J., Stuart C.A., Brodows R.G., Schwartz S., Graf C.J., Zagar A., Robertson K.E. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care. 23(9):2000;1236- 1241.
5. Boehm B., Home P.D., Bott U., Behrend C., Kamp N.M., Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabetic Medicine. 19:2002;393-399.
6. Bonora E., Calcaterra F., Lombardi S., Bonfante N., Formentini G., Bonadonna R.C. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Diabetes Care. 24(12):2001;2023-2029.
7. Cusi K., DeFronzo R.A. Metformin: a review of its metabolic effects. Diabetes Reviews. 6(2):1998;89-131.
8. DeFronzo R.A., Barzilai N., Simonson C. Mechanism of metformin action in obese and lean non-insulin dependent diabetic patients. Journal of Clinical Endocrinology and Metabolism. 73:1991;1294-1301.
9. Dunn C.J., Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 49(5):1995;721-749.
10. Hermansen K., Colombo M., Storgaard H., Østergaard A., Kølendorf K., Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 25(5):2002;883-888.
11. Kilo C. Value of glucose control in preventing complications of diabetes. American Journal of Medicine. 79(S28):1985;33-37.
12. Kilo C. Metformin: a safe and effective treatment in the management of NIDDM. Missouri Medicine. 94(3):1997;114-122.
13. McSorley P.T., Bell P.M., Jacobsen L.V., Kristensen A., Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind crossover study in adults with type 2 diabetes mellitus. Clinical Therapeutics. 24(4):2002;530-539.
14. Riddle M.C., Hart J., Bingham P., Garrison C., McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. American Journal of Medicine and Science. 303:1992;151-156.
15. Riddle M.C., Hart J.S., Bouma D.J., Phillipson B.E., Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetes patients. Diabetes Care. 12:1989;623-629.
16. Rohlfing C.L., Wiedmeyer H.M., Little R.R., England J.K., Tennill A., Goldstein D.E. Defining the relationship between plasma glucose and HbA1c. Diabetes Care. 25(2):2002;275-278.
17. Shank M.L., DelPrato S., DeFronzo R.A. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes. 44:1995;165-172.
18. United Kingdom Prospective Diabetes Study (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
19. Wulffele M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Van der Burg B.B., Donker A.J.M., Stehouwer C.D.A. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 25:2002;2133-2140.
20. Yki-Järvinen H., Kauppila M., Kujansuu E., Lahti J., Marjanen T., Niskanen L., Rajala S., Ryysy L., Salo S., Seppälä P. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. New England Journal of Medicine. 327(20):1992;1426-1433.